Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

Guardado en:

Detalles Bibliográficos
Autores principales:	Catherine R. Hanna, Sean M. O’Cathail, Janet S. Graham, Mark Saunders, Leslie Samuel, Mark Harrison, Lynsey Devlin, Joanne Edwards, Daniel R. Gaya, Caroline A. Kelly, Liz-Anne Lewsley, Noori Maka, Paula Morrison, Louise Dinnett, Susan Dillon, Jacqueline Gourlay, Jonathan J. Platt, Fiona Thomson, Richard A. Adams, Campbell S. D. Roxburgh
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c77f52c206394dd99ab532798ab8accd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c77f52c206394dd99ab532798ab8accd
record_format	dspace
spelling	oai:doaj.org-article:c77f52c206394dd99ab532798ab8accd2021-12-05T12:10:24ZCorrection to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)10.1186/s13014-021-01941-z1748-717Xhttps://doaj.org/article/c77f52c206394dd99ab532798ab8accd2021-12-01T00:00:00Zhttps://doi.org/10.1186/s13014-021-01941-zhttps://doaj.org/toc/1748-717XCatherine R. HannaSean M. O’CathailJanet S. GrahamMark SaundersLeslie SamuelMark HarrisonLynsey DevlinJoanne EdwardsDaniel R. GayaCaroline A. KellyLiz-Anne LewsleyNoori MakaPaula MorrisonLouise DinnettSusan DillonJacqueline GourlayJonathan J. PlattFiona ThomsonRichard A. AdamsCampbell S. D. RoxburghBMCarticleMedical physics. Medical radiology. Nuclear medicineR895-920Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENRadiation Oncology, Vol 16, Iss 1, Pp 1-1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Medical physics. Medical radiology. Nuclear medicine R895-920 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Catherine R. Hanna Sean M. O’Cathail Janet S. Graham Mark Saunders Leslie Samuel Mark Harrison Lynsey Devlin Joanne Edwards Daniel R. Gaya Caroline A. Kelly Liz-Anne Lewsley Noori Maka Paula Morrison Louise Dinnett Susan Dillon Jacqueline Gourlay Jonathan J. Platt Fiona Thomson Richard A. Adams Campbell S. D. Roxburgh Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
format	article
author	Catherine R. Hanna Sean M. O’Cathail Janet S. Graham Mark Saunders Leslie Samuel Mark Harrison Lynsey Devlin Joanne Edwards Daniel R. Gaya Caroline A. Kelly Liz-Anne Lewsley Noori Maka Paula Morrison Louise Dinnett Susan Dillon Jacqueline Gourlay Jonathan J. Platt Fiona Thomson Richard A. Adams Campbell S. D. Roxburgh
author_facet	Catherine R. Hanna Sean M. O’Cathail Janet S. Graham Mark Saunders Leslie Samuel Mark Harrison Lynsey Devlin Joanne Edwards Daniel R. Gaya Caroline A. Kelly Liz-Anne Lewsley Noori Maka Paula Morrison Louise Dinnett Susan Dillon Jacqueline Gourlay Jonathan J. Platt Fiona Thomson Richard A. Adams Campbell S. D. Roxburgh
author_sort	Catherine R. Hanna
title	Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
title_short	Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
title_full	Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
title_fullStr	Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
title_full_unstemmed	Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
title_sort	correction to: durvalumab (medi 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase ii trial (prime-rt)
publisher	BMC
publishDate	2021
url	https://doaj.org/article/c77f52c206394dd99ab532798ab8accd
work_keys_str_mv	AT catherinerhanna correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT seanmocathail correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT janetsgraham correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT marksaunders correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT lesliesamuel correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT markharrison correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT lynseydevlin correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT joanneedwards correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT danielrgaya correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT carolineakelly correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT lizannelewsley correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT noorimaka correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT paulamorrison correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT louisedinnett correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT susandillon correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT jacquelinegourlay correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT jonathanjplatt correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT fionathomson correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT richardaadams correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert AT campbellsdroxburgh correctiontodurvalumabmedi4736incombinationwithextendedneoadjuvantregimensinrectalcancerastudyprotocolofarandomisedphaseiitrialprimert
_version_	1718372218311802880

Correction to: Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

Ejemplares similares